ClinicalTrials.gg
CompletedNCT03351699Updated Oct 30, 2019Results posted

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

A Phase 1 interventional study of MK-4250 in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-4250 monotherapy in anti-retroviral therapy (ART)-naïve, HIV-1 infected participants. The primary hypothesis of the study is that at a dose that is sufficiently safe and generally well tolerated, MK-4250 has superior antiretroviral activity compared to a historical placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) (log10 copies/mL) at 168 hours postdose.

Read the detailed description

The study consists of 5 panels; Panel C (MK-4250 ≤600 mg) was removed from the study with Protocol Amendment 1.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-breast feeding female
  • If female with : must demonstrate a serum β-human chorionic gonadotropin (β -hCG) level consistent with the nongravid state and agree to use a highly effective method of until 30 days after the dose of trial drug
  • If female: without menses for at least 1 year and has a documented follicle stimulating hormone (FSH) level in the postmenopausal range at pretrial (screening), AND/OR status post hysterectomy or oophorectomy
  • Documented -1 positive as determined by a positive Enzyme-linked Immunosorbent Assay (ELISA) or Quantitative Polymerase Chain Reaction (-PCR) with confirmation (e.g., Western Blot).
  • No evidence at screening for mutations (e.g., E92Q, N55H, Q148K, Q148R and Y143R) affecting susceptibility to Integrase Strand Transfer Inhibitors (InSTIs)
  • Diagnosed with HIV-1 infection ≥ 3 months prior to screening or confirmed chronic HIV infection
  • Screening plasma Cluster of Differentiation (CD) 4+ T cell count of >200/mm\^3
  • Screening plasma HIV-1 RNA ≥5,000 copies/mL within 30 days prior to the treatment phase of this study
  • Anti-retroviral therapy (ART)-naïve, which is defined as having never received any antiretroviral agent OR ≤30 consecutive days of an antiretroviral agent which is not an InSTI and no exposure to such an investigational antiretroviral agent within 60 days prior to screening OR ≤60 consecutive days of combination ART which does not include an InSTI and no exposure to such ART within 60 days prior to screening
  • Never received any InSTI
  • Willing to receive no other ART for the duration of the treatment phase of this study
  • (BMI) ≤35 kg/m\^2
  • Other than HIV infection, have baseline health judged to be stable

Exclusion criteria

Exclusion Criteria:

  • Mentally or legally institutionalized / incapacitated, or significant emotional problems at the time of pretrial (screening) visit or expected during the conduct of the trial or has a history of psychiatric disorder within the last 5 years
  • History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of -1 infection), renal, respiratory, genitourinary or major neurological abnormalities or diseases
  • History of cancer (). Exceptions: (1) adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix; (2) other malignancies which have been successfully treated ≥10 years prior to the pretrial (screening) visit with no evidence of recurrence; or, (3) deemed highly unlikely to sustain a recurrence for the duration of the trial
  • History of significant multiple and/or severe allergies (e.g., food, drug, latex allergy); anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or non-prescription drugs or food; or hereditary galactose intolerance, lactose deficiency, or glucose-galactose malabsorption.
  • Positive for surface antigen
  • History of chronic (HCV) infection. Participants with a documented cure and/or a positive serologic test for HCV with a negative HCV viral load may be included
  • Major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit
  • Participated in another trial within 4 weeks prior to the Day 1 dosing visit. The 4 week window will be derived from the date of the last trial medication and / or blood collection in a previous trial and/or an adverse event related to trial drug to the Day 1 dosing visit of the current trial
  • Unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies beginning approximately 2 weeks prior to administration of the initial dose of trial drug, throughout the trial, until the post-trial visit
  • Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce]) per day. Participants who consume 4 glasses of alcoholic beverages per day may be enrolled
  • Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy-drinks, or other caffeinated beverages per day
  • Excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict smoking to ≤10 cigarettes per day
  • Cardiac ≥470 msec (for males) or ≥480 msec (for females)
  • Positive urine drug screen (except for cannabis) at screening and/or predose; rechecks are allowed
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Panel A: MK-4250 150 mg

    Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.

    Drug: MK-4250

  • Experimental
    Panel B: MK-4250 600 mg

    Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.

    Drug: MK-4250

  • Experimental
    Panel D: MK-4250 900 mg

    Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.

    Drug: MK-4250

  • Experimental
    Panel E: MK-4250 ≤900 mg with a Low-fat Meal

    Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.

    Drug: MK-4250

  • Experimental
    Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal

    Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.

    Drug: MK-4250

Interventions

  • DrugMK-4250

    MK-4250 tablets for oral administration

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours

    Plasma HIV-1 RNA was measured at Baseline and 168 hours after dosing. The log10 plasma HIV-RNA copies/mL measurements from participants in each panel were pooled and analyzed based on a longitudinal data analysis model. The change from Baseline in plasma HIV-1 RNA in participants administered MK-4250 was compared with historical placebo data.

    Time frame: Baseline and Day 7

  2. Percentage of Participants Experiencing ≥1 Adverse Events (AE)

    The percentage of participants experiencing ≥1 AE was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.

    Time frame: Up to Day 14

  3. Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE)

    The percentage of participants who discontinued from the study due to an adverse event was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.

    Time frame: Up to Day 14

Secondary outcomes

  1. Area Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250

    The area under the concentration-time curve up to the last measurable concentration (AUC0-last) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

  2. Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250

    The area under the concentration-time curve extrapolated to infinity (AUC0-inf) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

  3. Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250

    The area under the concentration-time curve up to 168 hours (AUC0-168) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, and 168 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time.

  4. Maximum Concentration (Cmax) of MK-4250 Reached in Plasma

    The maximum concentration (Cmax) of MK-4250 in plasma was observed.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

  5. Concentration of MK-4250 at 168 Hours (C168hr)

    The concentration of MK-4250 at 168 hours postdose (C168hr) was observed.

    Time frame: 168 hours after administration of MK-4250.

  6. Apparent Terminal Half-life (t1/2) of MK-4250

    The apparent terminal half-life (t1/2) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

  7. Apparent Clearance (CL/F) of MK-4250

    The apparent clearance (CL/F) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

  8. Apparent Volume of Distribution (Vz/F) of MK-4250

    The apparent volume of distribution (Vz/F) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

  9. Time to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma

    The time to maximum concentration (Vz/F) of MK-4250 in plasma was calculated.

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.

07

Results

Posted Oct 30, 2019

Participant flow

Participant flow — Overall Study
MilestonePanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Started66660
Completed66660
Not completed00000

Outcome measures

PrimaryChange From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours

Plasma HIV-1 RNA was measured at Baseline and 168 hours after dosing. The log10 plasma HIV-RNA copies/mL measurements from participants in each panel were pooled and analyzed based on a longitudinal data analysis model. The change from Baseline in plasma HIV-1 RNA in participants administered MK-4250 was compared with historical placebo data.

Time frame:
Baseline and Day 7
Reported as:
Least squares mean · log10 copies per mL
Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours
log10 copies per mLPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours-1.56 (-1.88 to -1.23)-1.76 (-2.08 to -1.43)-1.55 (-1.87 to -1.23)-1.78 (-2.10 to -1.45)—
Statistical analysis
  • Panel A: MK-4250 150 mg · Posterior mean difference: -1.53Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between MK-4250 and placebo at least 1.4 log10 copies/mL was 78%.
  • Panel B: MK-4250 600 mg · Posterior mean difference: -1.73Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between MK-4250 and placebo at least 1.4 log10 copies/mL was 95%.
  • Panel D: MK-4250 900 mg · Posterior mean difference: -1.52Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between MK-4250 and placebo at least 1.4 log10 copies/mL was 75%.
  • Panel E: MK-4250 ≤900 mg With a Low-fat Meal · Posterior mean difference: -1.75Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between MK-4250 and placebo at least 1.4 log10 copies/mL was 96%.
PrimaryPercentage of Participants Experiencing ≥1 Adverse Events (AE)

The percentage of participants experiencing ≥1 AE was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.

Time frame:
Up to Day 14
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing ≥1 Adverse Events (AE)
Percentage of ParticipantsScreeningPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Percentage of Participants Experiencing ≥1 Adverse Events (AE)8.383.366.783.366.7—
PrimaryPercentage of Participants Who Discontinued Study Due to an Adverse Event (AE)

The percentage of participants who discontinued from the study due to an adverse event was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.

Time frame:
Up to Day 14
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE)
Percentage of ParticipantsScreeningPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE)0.00.00.00.00.0—
SecondaryArea Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250

The area under the concentration-time curve up to the last measurable concentration (AUC0-last) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Geometric mean · μM·hour
Area Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250
μM·hourPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Area Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250774 ± 542040 ± 17.12390 ± 353860 ± 44.3—
SecondaryArea Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250

The area under the concentration-time curve extrapolated to infinity (AUC0-inf) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Geometric mean · μM·hour
Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250
μM·hourPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250785 ± 54.62120 ± 18.42450 ± 35.94010 ± 47.6—
SecondaryArea Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250

The area under the concentration-time curve up to 168 hours (AUC0-168) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, and 168 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time.
Reported as:
Geometric mean · μM·Hour
Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250
μM·HourPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250751 ± 52.61980 ± 16.72280 ± 34.13640 ± 41.2—
SecondaryMaximum Concentration (Cmax) of MK-4250 Reached in Plasma

The maximum concentration (Cmax) of MK-4250 in plasma was observed.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Geometric mean · μM
Maximum Concentration (Cmax) of MK-4250 Reached in Plasma
μMPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Maximum Concentration (Cmax) of MK-4250 Reached in Plasma16.6 ± 46.737.6 ± 2643.5 ± 32.765 ± 25.8—
SecondaryConcentration of MK-4250 at 168 Hours (C168hr)

The concentration of MK-4250 at 168 hours postdose (C168hr) was observed.

Time frame:
168 hours after administration of MK-4250.
Reported as:
Geometric mean · μM
Concentration of MK-4250 at 168 Hours (C168hr)
μMPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Concentration of MK-4250 at 168 Hours (C168hr)0.558 ± 1172.2 ± 57.42.38 ± 63.84.37 ± 96.4—
SecondaryApparent Terminal Half-life (t1/2) of MK-4250

The apparent terminal half-life (t1/2) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Geometric mean · Hours
Apparent Terminal Half-life (t1/2) of MK-4250
HoursPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Apparent Terminal Half-life (t1/2) of MK-425035.9 ± 22.938.5 ± 31.944.1 ± 17.148.4 ± 32.1—
SecondaryApparent Clearance (CL/F) of MK-4250

The apparent clearance (CL/F) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Geometric mean · Liters/Hour
Apparent Clearance (CL/F) of MK-4250
Liters/HourPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Apparent Clearance (CL/F) of MK-42500.456 ± 54.60.676 ± 18.40.879 ± 35.90.536 ± 47.6—
SecondaryApparent Volume of Distribution (Vz/F) of MK-4250

The apparent volume of distribution (Vz/F) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of MK-4250
LitersPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Apparent Volume of Distribution (Vz/F) of MK-425023.6 ± 45.137.6 ± 23.556 ± 31.737.4 ± 17.5—
SecondaryTime to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma

The time to maximum concentration (Vz/F) of MK-4250 in plasma was calculated.

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma
HoursPanel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat Meal
Time to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma4.00 (1.00 to 4.00)4.00 (4.00 to 6.00)4.00 (4.00 to 6.00)4.00 (4.00 to 8.00)—

Adverse events

Collected over Up to 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Screening0/24 (0%)0/24 (0%)2/24 (8.3%)
Panel A: 150 mg MK-42500/6 (0%)0/6 (0%)5/6 (83.3%)
Panel B: 600 mg MK-42500/6 (0%)0/6 (0%)4/6 (66.7%)
Panel D: 900 mg MK-42500/6 (0%)0/6 (0%)5/6 (83.3%)
Panel E: 900 mg MK-4250, With a Low Fat Meal0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventScreeningPanel A: 150 mg MK-4250Panel B: 600 mg MK-4250Panel D: 900 mg MK-4250Panel E: 900 mg MK-4250, With a Low Fat Meal
HeadacheNervous system disorders2/244/62/61/63/6
DiarrhoeaGastrointestinal disorders0/241/63/61/60/6
NasopharyngitisInfections and infestations0/243/60/61/60/6
Aphthous ulcerGastrointestinal disorders0/240/60/62/60/6
DizzinessNervous system disorders0/242/60/61/60/6
LymphadenitisBlood and lymphatic system disorders0/240/60/61/60/6
Abdominal painGastrointestinal disorders0/240/61/60/60/6
Dry mouthGastrointestinal disorders0/240/60/61/60/6
NauseaGastrointestinal disorders0/241/61/60/60/6
VomitingGastrointestinal disorders0/241/61/60/60/6

Baseline characteristics

Panel F did not enroll because the scientific objectives were met following completion of Panel E.

Age, Continuous
Age, Continuous(Years)Panel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat MealTotal
Mean36.3 ± 8.132.5 ± 6.136.5 ± 8.935.5 ± 7.3—35.2 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat MealTotal
Female000000
Male6666024
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat MealTotal
Hispanic or Latino100001
Not Hispanic or Latino5666023
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat MealTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White6666024
More than one race000000
Unknown or Not Reported000000
Baseline Plasma HIV-1 Ribonucleic Acid (RNA)
Baseline Plasma HIV-1 Ribonucleic Acid (RNA)(log10 copies/mL)Panel A: MK-4250 150 mgPanel B: MK-4250 600 mgPanel D: MK-4250 900 mgPanel E: MK-4250 ≤900 mg With a Low-fat MealPanel F: MK-4250 ≤900 mg With a Moderate-fat MealTotal
Mean4.29394 ± 0.412004.42577 ± 0.395774.85677 ± 0.237904.42262 ± 0.37308—4.49978 ± 0.40099
08

Study locations

1 site
  • Charite Research Organisation GmbH ( Site 0001)
    Berlin, 10117, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Nov 2018, 9 months.

Results were first posted in Oct 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 24, 2017
StartActual
Jan 18, 2018
Primary completionActual
Nov 2, 2018
CompletionActual
Nov 2, 2018
Results first posted
Oct 30, 2019
Last update
Oct 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03351699
Responsible party
Sponsor
First posted
Nov 24, 2017
Start date
Jan 18, 2018
Primary completion
Nov 2, 2018
Completion
Nov 2, 2018
Results posted
Oct 30, 2019
Last update
Oct 30, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion